Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $136 to $156.
Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $136 to $156.